Peptide News Digest

Pfizer's $1.5B Blackstone Deal for Berobenatide, Korea Allows Mounjaro Carry-Ins, Aspen's Generic Semaglutide

Blackstone funds up to $1.5B of Pfizer's monthly GLP-1, Korea allows GLP-1 carry-ins from abroad, and Aspen gets generic semaglutide approved in two countries.

10 stories · Covering industry, regulatory, research, clinical-trials

Editor's Note

Price gaps between countries drove two of the day's regulatory stories. South Korea will let travelers bring home up to a three-month supply of Wegovy or Mounjaro bought legally abroad after customs caught 1,097 unauthorized imports in eight months; a starter month of Mounjaro reportedly costs about a third as much at some Japanese clinics. Aspen's approvals for generic semaglutide in Brazil and South Africa add to the patent-expiry markets where Novo Nordisk now faces cheaper copies. Pfizer, meanwhile, is paying for its late entry into obesity partly with outside money: Blackstone will cover up to $1.5 billion of berobenatide's development in return for milestone payments, without taking any rights to the drug. A Nature Metabolism study adds a genetic wrinkle to drug choice: 17 semaglutide users carrying rare damaging GLP1R variants lost 2.4% of their weight versus 8.8% for matched non-carriers, while carriers on tirzepatide did nearly as well as everyone else. Outside obesity, three peptide papers stayed early-stage: a University of Macau team mined bacterial genomes for colistin-like peptides that worked in mice, a Barcelona group tested SET-M33 against drug-resistant poultry bacteria in the lab, and an interim analysis of a BPC-157 and GHK-Cu hair serum reported that women felt better about their hair, though its authors say it does not show the product works.

Blackstone Will Pay Up to $1.5 Billion of Development Costs for Pfizer's Monthly GLP-1 Drug Berobenatide Through 2028

Funds managed by Blackstone Life Sciences will cover up to $1.5 billion of development costs through 2028 for berobenatide (PF'3944), Pfizer's investigational once-monthly GLP-1 receptor agonist peptide, in exchange for milestone payments tied to U.S. approval of monthly berobenatide for chronic weight management and to sales targets, Pfizer said on November 11. Blackstone gets no rights or ownership in the drug, and Pfizer keeps full control of the program, which includes 10 ongoing and planned Phase 3 trials covering weight management, knee osteoarthritis, and obstructive sleep apnea.

South Korea Will Let Travelers Bring In Up to a Three-Month Supply of Wegovy and Mounjaro Bought Legally Abroad

Starting November 12, people who legally bought weight-loss drugs such as Wegovy and Mounjaro overseas for their own treatment may bring them into South Korea in hand luggage, up to six units or a three-month supply, the Ministry of Food and Drug Safety and the Korea Customs Service said. Customs detected 1,097 unauthorized imports of the two drugs from January to August, more than eight times the 134 cases in all of 2025, The Korea Herald reported; a four-week supply of the lowest Mounjaro dose costs about 300,000 won ($225) in Korea, while some Japanese clinics reportedly charge about 100,000 won. Officials warned about improper refrigeration, misuse, and resale.

Aspen Pharmacare Wins Approval for Generic Semaglutide Injections in Brazil and South Africa, With Launches Expected Within Months

Africa's largest drugmaker received regulatory approval for its generic injectable semaglutide in Brazil and South Africa after a Canadian approval in July, Business Day reported on November 11; it is registered for adults with type 2 diabetes, and doctors may prescribe it off label for weight management. CFO Sean Capazorio would say only that it will be priced below Novo Nordisk's Ozempic and Wegovy. South Africa's regulator approved Ranbaxy's Semagard in July and Novo's own Semditu in October, and Aspen will first make the drug in India before moving production to South Africa and France.

Arizona, Florida, Nebraska, Ohio, and Wisconsin Join the FTC's Privacy and Billing Lawsuit Against Hims & Hers

The FTC filed an amended complaint in federal court in Northern California adding five states to its July lawsuit, which alleges that Hims & Hers shared consumers' sensitive health information with advertising platforms including Meta and Snap despite privacy promises and misled users about billing and cancellation, Reuters reported on November 10. Los Angeles County and Utah joined the original suit. A Hims & Hers spokesperson said the company will "vigorously defend" itself against what it called follow-on claims.

Nature Metabolism: Carriers of Rare GLP1R Variants Lost Less Weight on Semaglutide but Responded Almost Normally to Tirzepatide

Using exome sequencing and health records from 13 North American health systems in the Helix Research Network, researchers studied 13,725 adults who started semaglutide or tirzepatide. Among semaglutide users, 17 carriers of rare GLP1R variants lost 2.4% of body weight vs. 8.8% in matched non-carriers, while 19 carriers on tirzepatide lost 13.3% vs. 15.2%, a difference that was not statistically significant; carriers of rare GIPR variants had near-normal responses. Follow-up was capped at 12 months, and the carrier groups were small.

Lilly's TOGETHER-PsA: 43.7% on Taltz Plus Zepbound vs. 15.7% on Taltz Alone Reached ACR50 at One Year in Psoriatic Arthritis With Obesity

In the open-label, assessor-blinded Phase 3b TOGETHER-PsA trial of 271 adults with active psoriatic arthritis and obesity or overweight with a weight-related condition, 43.7% of those taking Taltz with Zepbound and 15.7% of those on Taltz alone had at least a 50% reduction in disease activity (ACR50) at 52 weeks, Lilly said on November 11. The one-year comparisons are exploratory and not controlled for multiple testing; the Week 36 primary endpoint had already favored the combination. Results were presented at ACR Convergence 2026 and published in Arthritis & Rheumatology.

British Virgin Islands Health Ministry Warns Residents Against Weight-Loss Injections and Peptides Sold Through WhatsApp and Facebook

The Ministry of Health and Social Development said on November 11 that weight-loss injections and peptides are being offered in the territory through closed WhatsApp groups and Facebook pages and imported by courier for personal use or resale. Chief Medical Officer Ronald Georges told residents to get them only through legitimate medical and pharmacy channels, and the ministry said anyone who already has such products should stop taking them until they consult a doctor or pharmacist, warning that unlawful sale or administration may lead to enforcement action.

University of Macau Team Mines 954 Bacterial Genomes for Colistin-Like Peptides; Lead Candidate NP001 Saved Half of Mice With Resistant Infections

Researchers reconstructed antimicrobial peptides from incomplete gene clusters in 954 Paenibacillus genomes and found five polymyxin-like peptides, NP001 to NP005. In mice infected with colistin-resistant E. coli carrying the MCR-1 gene, NP001 cut bacterial loads in thigh tissue by up to 1,000-fold, and 50% of NP001-treated mice survived lethal peritonitis vs. none given colistin or saline, the Cell Reports Medicine paper reports; the university publicized the work on November 11.

Barcelona Lab Study: Synthetic Peptide SET-M33 Inhibited 141 Drug-Resistant Poultry Bacteria Isolates Without Harming Chicken Gut Organoids

Researchers at IRTA-CReSA in Barcelona tested SET-M33, a synthetic four-branched antimicrobial peptide, against 141 field isolates of E. coli, Salmonella enterica, Enterococcus faecalis, and Enterococcus cecorum from poultry, including multidrug-resistant strains. Median minimum inhibitory concentrations were 2.5 μM for Gram-negative and 5 μM for Gram-positive bacteria, and the peptide kept working in chicken intestinal organoid co-cultures at doses that spared the host cells, the Microbiology Spectrum paper reports. The work was done in the lab, not in birds.

Hair-Thinning Trial Interim: Women Using a GHK-Cu, Thymulin, and BPC-157 Serum Reported Less Distress, With No Comparison Group Yet

In an interim, single-site analysis of a randomized trial in women aged 28 to 65 with androgenetic alopecia, 43 of 54 enrolled women had follow-up questionnaires after using a topical peptide serum (GHK-Cu, zinc thymulin, BPC-157) with an oral supplement gummy. Hair-related distress scores fell 24% after 3 months and 43% after 9 months on the products, and the share rating their hair loss as none or mild rose from 21% to 74% at 6 months, the abstract in SKIN: The Journal of Cutaneous Medicine reports. The authors say the unblinded, within-subject results describe patient experience rather than a demonstrated product effect, and hair-density data will come at the end of the study.